



(51) International Patent Classification: Not classified

(21) International Application Number:
PCT/GB2011/051256(22) International Filing Date:
4 July 2011 (04.07.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/361,585 6 July 2010 (06.07.2010) US(71) Applicant (for all designated States except MG, US): **ASTRAZENECA AB** [SE/SE]; S-151 85 Södertälje (SE).(71) Applicant (for MG only): **ASTRAZENECA UK LIMITED** [GB/GB]; 2 Kingdom Street, London Greater London W2 6BD (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BÖKMAN-WINIWARTER, Susanne, Doris, Margit** [AT/SE]; AstraZeneca R&D Mölndal, S-431 83 Mölndal (SE). **FREDENWALL, Marlene** [SE/SE]; AstraZeneca R&D Mölndal, S-431 83 Mölndal (SE). **HOGNER, Carl, Anders** [SE/SE]; AstraZeneca R&D Mölndal, S-431 83 Mölndal (SE). **JOHANSSON, Lars Anders, Mikael** [SE/SE]; AstraZeneca R&D Mölndal, S-431 83 Mölndal (SE). **JUDKINS, Robert, Andrew** [GB/SE]; AstraZeneca R&D Mölndal, S-431 83 Mölndal (SE). **LI, Lanna** [SE/SE]; AstraZeneca R&D Mölndal, S-431 83 Mölndal (SE). **LÖFBERG, Björn, Christian, Ingvar** [SE/SE]; As-traZeneca R&D Mölndal, S-431 83 Mölndal (SE). **VON UNGE, Sverker** [SE/SE]; AstraZeneca R&D Mölndal, S-431 83 Mölndal (SE).(74) Agent: **ASTRAZENECA INTELLECTUAL PROPERTY**; AstraZeneca AB, S-151 85 Södertälje (SE).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report (Rule 48.2(g))

(54) Title: THERAPEUTIC AGENTS 976



(57) Abstract: Disclosed herein are azetidiny compounds of formula (I), as described herein, pharmaceutical compositions comprising an azetidiny compound, and a method of using an azetidiny compound in the treatment or prophylaxis of a melanin-concentrating hormone related disease or condition.